OCS logo

OCULIS HOLDING AG

OCSNASDAQ
🏆 #2750 by market capUS Equity
$711.34▼ $2.42 (−0.34%)
Simulated price
🔔
Track OCS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.3%
7d▲ 6554.3%
14d▲ 6985.1%
30d▲ 5692.7%
ytd▲ 3463.8%
1y▲ 3930.3%
🏦Market Cap
$688M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
68
Fair

Trading Snapshot

Day Range
$702.37 – $722.39
52-Week Range
—
Volume
$6.37B
Avg Volume
$4.46B
Shares Outstanding
62.0M
Next Earnings
Nov 20, 2026

Fundamentals Snapshot

Annual Revenue
$58M
Last Q Revenue
$16M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+33.9%

Why Investors Own OCS

  • ✓High-growth profile — revenue up +59.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 45% gross margin and 13% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

OCS logo

OCULIS HOLDING AG

OCS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$79M▲ +8.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$63M▲ +31.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
56.0M▲ +33.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$79M▲ +$53M YoY
StockOtter · stockotter.space

About OCULIS HOLDING AG

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$825.91
▲ +16.1% Upside
High Target$1,030.21
Low Target$749.58
Based on 9 analysts

Latest News & Updates

🚀
Barron’s·2h ago

OCULIS HOLDING AG tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift OCS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

OCULIS HOLDING AG announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.